Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NovoCure Ltd.
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Hoffmann-La Roche
Dragonfly Therapeutics
Pfizer
National Cancer Institute (NCI)
BeOne Medicines
Dragonfly Therapeutics
National Cancer Institute (NCI)
Mirati Therapeutics Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Synthekine
BeOne Medicines
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Dragonfly Therapeutics
Frontier Medicines Corporation
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI)
University Hospital, Tours
Boehringer Ingelheim
Fondazione del Piemonte per l'Oncologia
Hôpital du Valais
Merck Sharp & Dohme LLC
Duke University
National Cancer Institute (NCI)
Centre Oscar Lambret
National Institutes of Health Clinical Center (CC)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Daiichi Sankyo
Gilead Sciences
Bristol-Myers Squibb
BioNTech SE